A Phase II trial of high dose epirubicin in patients with advanced breast carcinoma

Клики: 460
ID: 271757
2000
Бесплатный PDF
Метрики качества и эффективности статьи
Общее качество
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
Оценка качества ИИ
Не проанализировано
Readership in this journal
Popular

Ranked #2 of 32 articles by views in cancer

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Аннотация
BACKGROUND Anthracyclines are among the most active drugs in the treatment of breast carcinoma and exhibit a steep dose‐response curve in vitro. This trial was performed to determine the efficacy and toxicity of epirubicin in the treatment of patients with advanced breast carcinoma when administered as a single agent in maximal doses. METHODS Patients with chemotherapy‐naïve American Joint Committee on Cancer/International Union Against Cancer Stage IIIB or IV breast carcinoma received epirubicin, 180 mg/m2, intravenously every 3 weeks for a maximum of 8 cycles of therapy. Hematopoietic growth factors and cardioprotective agents were not used routinely. RESULTS Twenty‐seven patients were entered in the study. Although NCI/CTC criteria Grade 4 neutropenia occurred in 96% of patients, epirubicin was administered at 83.1% of the planned dose intensity. The median fall in left ventricular ejection fraction was 10%; clinical cardiac toxicity was observed in 3 patients. Objective responses were observed in 21 patients, including 6 complete responses. CONCLUSIONS High dose epirubicin was found to result in substantial hematologic toxicity but was highly active in the treatment of patients with advanced breast carcinoma. Cancer 2000;88:375–80. © 2000 American Cancer Society.
Ссылочный ключ
sledge2000cancera Используйте этот ключ для автоцитирования в рукописи при использовании SciMatic Manuscript Manager или Thesis Manager
Авторы Kathy D. Miller,Nikhil Munshi,David Loesch,Lawrence H. Einhorn M.D.,George W. Sledge;Kathy D. Miller;Nikhil Munshi;David Loesch;Lawrence H. Einhorn M.D.;George W. Sledge;
Журнал cancer
Год 2000
DOI
10.1002/(sici)1097-0142(20000115)88:23.0.co;2-m
URL
https://sciprofiles.com/publication/view/f3b7c690cade78003a81cbb2db19e335
Ключевые слова
Chemotherapy metastatic breast epirubicin breast carcinoma dose intensity anthracycline

Цитирования

Цитирования не найдены. Чтобы добавить цитирование, свяжитесь с администратором по адресу info@scimatic.org

Комментарии

Комментариев пока нет. Будьте первым, кто прокомментирует эту статью.